Cell-Specific Aptamers for Targeted Therapies
Many signalling proteins involved in diverse functions such as cell growth and differentiation can act as oncogenes and cause cellular transformation. These molecules represent attractive targets for cancer diagnosis or therapy and therefore are subject to intensive investigation.
Aptamers are small, highly structured nucleic acid molecules, isolated from combinatorial libraries by a procedure termed SELEX. Aptamers bind to a target molecule by providing a limited number of specific contact points imbedded in a larger, defined three-dimensional structure. Recently, aptamers have been selected against whole living cells, opening a new path which presents three major advantages: (1) direct selection without prior purification of membrane-bound targets, (2) access to membrane proteins in their native conformation similar to the in vivo conditions and (3) identification of (new) targets related to a specific phenotype. The ability to raise aptamers against living cells opens some attractive possibilities for new therapeutic and delivery approaches. In this chapter, the most recent advances in the field will be reviewed together with detailed descriptions of the relevant experimental approaches.
Key wordsAptamer SELEX ret delivery siRNA
This work was supported by the European Molecular Imaging Laboratory (EMIL) Network (LSHC-2004-503569) and by the MIUR-FIRB Grant (#RBIN04J4J7).
We wish to thank C.L. Esposito, B. Tavitian, F. Duconge and D. Libri for fruitful discussions.
- 2.Ellington, A.D. and Szostak, J.W. (1990) In vitro selection of RNA molecules that bind specific ligands. Science 346, 818–822.Google Scholar
- 5.Ruckman, J., Green, L.S., Beeson, J., Waugh, S., Gillette, W.L., Henninger, D.D., Claesson-Welsh, L. and Janjic, N. (1998) 2'-Fluoropyrimidine RNA-based aptamers to the 165-amino acid form of vascular endothelial growth factor (VEGF165). Inhibition of receptor binding and VEGF-induced vascular permeability through interactions requiring the exon 7-encoded domain. J. Biol. Chem. 273, 20556–20567.PubMedCrossRefGoogle Scholar
- 7.Morris, K.N., Jensen, K.B, Julin, C.M., Weil, M., Gold, L. (1998) High affinity ligands from in vitro selection: complex targets. Proc. Natl. Acad. Sci. U.S.A. 95, 2902–2907.Google Scholar
- 19.Song, E., Zhu, P., Lee, S., Chowdhury, D., Kussman, S., Dykxhoorn, D.M., Feng, Y., Palliser, D., Weiner, D.B., Shankar, P., Marasco, W.A. and Lieberman, J. (2005) Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors.Nat. Biotechnol. 23, 709–717.PubMedCrossRefGoogle Scholar
- 21.Farokhzad, O.C., Cheng, J., Teply, B.A., Sherifi, I., Jon, S., Kantoff, P.W., Richie, J.P. and Langer, R. (2006) Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. Proc. Natl. Acad. Sci. U.S.A. 103, 6315–6320.Google Scholar
- 24.Chen, C.H., Chernis, G.A., Hoang, V.Q. and Landgraf, R. (2003). Inhibition of heregulin signaling by an aptamer that preferentially binds to the oligomeric form of human epidermal growth factor receptor-3. Proc. Natl. Acad. Sci. U.S.A. 100, 9226–9231.Google Scholar
- 26.Mi, J., Zhang, X., Giangrande, P.H., McNamara, J.O., 2nd, Nimjee, S.M., Sarraf-Yazdi, S., Sullenger, B.A. and Clary, B.M. (2005). Targeted inhibition of alphavbeta3 integrin with an RNA aptamer impairs endothelial cell growth and survival. Biochem. Biophys. Res. Commun. 338, 956–963.PubMedCrossRefGoogle Scholar